PT2167128E - Anticorpos híbridos anti-integrina alfa v manipulados - Google Patents

Anticorpos híbridos anti-integrina alfa v manipulados

Info

Publication number: PT2167128E
Authority: PT; Portugal
Prior art keywords: alpha; hybrid antibodies; engineered anti; integrin hybrid; integrin
Prior art date: 2007-07-17

Application number

PT87848347T

Other languages

English (en)

Inventor

Francesc Mitjans

Jaume Adan

Kin-Ming Lo

Simon Goodman

Diane Hahn

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-17

Filing date

2008-07-17

Publication date

2013-01-24

2008-07-17 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2013-01-24 Publication of PT2167128E publication Critical patent/PT2167128E/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Heart & Thoracic Surgery (AREA)
Oncology (AREA)
Cardiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT87848347T 2007-07-17 2008-07-17 Anticorpos híbridos anti-integrina alfa v manipulados PT2167128E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP07013964		2007-07-17

Publications (1)

Publication Number	Publication Date
PT2167128E true PT2167128E (pt)	2013-01-24

Family

ID=40029330

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT87848347T PT2167128E (pt)	2007-07-17	2008-07-17	Anticorpos híbridos anti-integrina alfa v manipulados

Country Status (19)

Country	Link
US (1)	US8562986B2 (pt)
EP (2)	EP2526967A1 (pt)
JP (1)	JP5341889B2 (pt)
KR (1)	KR101559596B1 (pt)
CN (1)	CN101687039B (pt)
AU (1)	AU2008277907B2 (pt)
BR (1)	BRPI0815567B8 (pt)
CA (1)	CA2693863C (pt)
CY (1)	CY1113493T1 (pt)
DK (1)	DK2167128T3 (pt)
EA (1)	EA019485B1 (pt)
ES (1)	ES2395799T3 (pt)
HR (1)	HRP20120949T1 (pt)
IL (1)	IL203269A (pt)
PL (1)	PL2167128T3 (pt)
PT (1)	PT2167128E (pt)
SI (1)	SI2167128T1 (pt)
WO (1)	WO2009010290A2 (pt)
ZA (1)	ZA201001124B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2747937C (en)	2008-12-23	2019-02-26	Merck Patent Gmbh	Biomarkers for inhibitors with anti-angiogenic activity
AU2010285265B2 (en)	2009-08-19	2015-05-21	Merck Patent Gmbh	Antibodies for the detection of integrin complexes in FFPE material
SG192667A1 (en) *	2011-02-11	2013-09-30	Merck Patent Gmbh	Anti-alpha-v integrin antibody for the treatment of prostate cancer
WO2015035215A1 (en) *	2013-09-05	2015-03-12	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
KR20170052690A (ko)	2014-09-17	2017-05-12	메르크 파텐트 게엠베하	고형암 및/또는 이의 전이 치료 방법, 그에 따른 약제, 및 고형암 및/또는 이의 전이 치료의 임상 결과 예측 방법
WO2016041616A1 (en)	2014-09-17	2016-03-24	Merck Patent Gmbh	A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
HRP20201756T8 (hr)	2014-11-21	2021-08-20	Bristol-Myers Squibb Company	Antitijela koja sadrže modificirane regije teškog lanca
TWI711630B (zh)	2014-11-21	2020-12-01	美商必治妥美雅史谷比公司	抗ｃｄ７３抗體及其用途
US20190144547A1 (en)	2015-11-23	2019-05-16	Merck Patent Gmbh	Anti-alpha-v integrin antibody for the treatment of fibrosis and/or fibrotic disorders
BR112018010337A2 (pt) *	2015-11-23	2018-12-04	Merck Patent Gmbh	anticorpo anti-alfa-v integrina para o tratamento de fibrose e/ou transtornos fibróticos
JP2019533139A (ja)	2016-09-08	2019-11-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	ネフローゼ症候群を診断及び処置するための方法
WO2018106931A1 (en)	2016-12-07	2018-06-14	Progenity Inc.	Gastrointestinal tract detection methods, devices and systems
TW201834710A (zh)	2016-12-14	2018-10-01	美商寶珍那提公司	以整合素抑制劑治療胃腸道疾病
WO2018141894A1 (en)	2017-02-02	2018-08-09	Merck Patent Gmbh	Preferred pairing of antibody domains
CN108948206B (zh) *	2017-05-23	2022-08-23	赵磊	一种抗egfr/pd-1双靶向抗体、其制备方法及用途
EP3692060A1 (en)	2017-10-03	2020-08-12	Merck Patent GmbH	Cysteine engineered antigen-binding molecules
US11339221B2 (en) *	2017-11-01	2022-05-24	Tufts Medical Center, Inc.	Bispecific antibody constructs and methods of use
WO2019246455A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
TW202027789A (zh)	2018-10-19	2020-08-01	德商馬克專利公司	用於治療大腸直腸癌之阿比特珠單抗(abituzumab)
CN116726361A (zh)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
US11707610B2 (en)	2019-12-13	2023-07-25	Biora Therapeutics, Inc.	Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN114366749B (zh) *	2020-10-15	2023-06-30	中国人民解放军海军军医大学	整合素抑制剂在制备治疗肾癌的药物中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1992015683A1 (en) *	1991-03-06	1992-09-17	MERCK Patent Gesellschaft mit beschränkter Haftung	Humanized and chimeric monoclonal antibodies
SI0719859T1 (en)	1994-12-20	2003-12-31	Merck Patent Gmbh	Anti-alpha V-integrin monoclonal antibody
JP3461945B2 (ja)	1994-12-26	2003-10-27	株式会社日本製鋼所	高低圧一体型タービンロータの製造方法
DE19534177A1 (de)	1995-09-15	1997-03-20	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
ATE319745T1 (de)	1997-05-21	2006-03-15	Biovation Ltd	Verfahren zur herstellung von nicht-immunogenen proteinen
DE19842415A1 (de)	1998-09-16	2000-03-23	Merck Patent Gmbh	Pharmazeutische Zubereitung
AU776910B2 (en)	1998-12-08	2004-09-23	Merck Patent Gesellschaft Mit Beschrankter Haftung	Modifying protein immunogenicity
EP1998266A3 (en)	2001-02-19	2009-02-11	Merck Patent GmbH	Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity
KR20110140143A (ko)	2002-11-26	2011-12-30	애보트 바이오테라퓨틱스 코포레이션	혈관형성을 조절하는 α5β1 인테그린에 대한 키메라성 및 인간화 항체
US8147832B2 (en) *	2003-08-14	2012-04-03	Merck Patent Gmbh	CD20-binding polypeptide compositions and methods
KR20060002667A (ko)	2004-07-03	2006-01-09	삼성전자주식회사	디스크 댐퍼와 디스크 프로텍터를 구비한 하드 디스크드라이브
PT1966245E (pt) *	2005-12-30	2011-08-31	Merck Patent Gmbh	Anticorpos anti-cd19 com imunogenicidade reduzida
US7669429B2 (en)	2006-01-19	2010-03-02	Bassler Sr G Scott	Rapid food chiller

2008
- 2008-07-17 EP EP12004296A patent/EP2526967A1/en not_active Withdrawn
- 2008-07-17 KR KR1020107003397A patent/KR101559596B1/ko not_active Expired - Fee Related
- 2008-07-17 EA EA201070150A patent/EA019485B1/ru not_active IP Right Cessation
- 2008-07-17 US US12/669,408 patent/US8562986B2/en not_active Expired - Fee Related
- 2008-07-17 CN CN200880024003.1A patent/CN101687039B/zh not_active Expired - Fee Related
- 2008-07-17 WO PCT/EP2008/005852 patent/WO2009010290A2/en not_active Ceased
- 2008-07-17 ES ES08784834T patent/ES2395799T3/es active Active
- 2008-07-17 BR BRPI0815567A patent/BRPI0815567B8/pt active IP Right Grant
- 2008-07-17 AU AU2008277907A patent/AU2008277907B2/en not_active Ceased
- 2008-07-17 HR HRP20120949AT patent/HRP20120949T1/hr unknown
- 2008-07-17 EP EP08784834A patent/EP2167128B1/en active Active
- 2008-07-17 PT PT87848347T patent/PT2167128E/pt unknown
- 2008-07-17 CA CA2693863A patent/CA2693863C/en active Active
- 2008-07-17 SI SI200830845T patent/SI2167128T1/sl unknown
- 2008-07-17 DK DK08784834.7T patent/DK2167128T3/da active
- 2008-07-17 PL PL08784834T patent/PL2167128T3/pl unknown
- 2008-07-17 JP JP2010516422A patent/JP5341889B2/ja not_active Expired - Fee Related
2010
- 2010-01-12 IL IL203269A patent/IL203269A/en active IP Right Grant
- 2010-02-16 ZA ZA2010/01124A patent/ZA201001124B/en unknown
2012
- 2012-12-21 CY CY20121101248T patent/CY1113493T1/el unknown

Also Published As

Publication number	Publication date
JP2010533480A (ja)	2010-10-28
AU2008277907B2 (en)	2013-08-22
HRP20120949T1 (en)	2012-12-31
ZA201001124B (en)	2010-11-24
US8562986B2 (en)	2013-10-22
AU2008277907A1 (en)	2009-01-22
EA201070150A1 (ru)	2010-08-30
CA2693863C (en)	2017-10-03
IL203269A (en)	2014-11-30
CN101687039B (zh)	2014-04-16
KR101559596B1 (ko)	2015-10-12
WO2009010290A2 (en)	2009-01-22
WO2009010290A3 (en)	2009-04-09
KR20100057010A (ko)	2010-05-28
CN101687039A (zh)	2010-03-31
BRPI0815567B1 (pt)	2019-06-04
EP2167128B1 (en)	2012-10-24
DK2167128T3 (da)	2012-12-03
CY1113493T1 (el)	2016-06-22
EP2526967A1 (en)	2012-11-28
PL2167128T3 (pl)	2013-03-29
HK1143523A1 (en)	2011-01-07
BRPI0815567B8 (pt)	2021-05-25
US20100254977A1 (en)	2010-10-07
ES2395799T3 (es)	2013-02-15
SI2167128T1 (sl)	2013-01-31
EP2167128A2 (en)	2010-03-31
BRPI0815567A2 (pt)	2015-02-18
JP5341889B2 (ja)	2013-11-13
EA019485B1 (ru)	2014-04-30
CA2693863A1 (en)	2009-01-22

Publication	Publication Date	Title
ZA201001124B (en)	2010-11-24	Engineered anti-alpha v-integrin hybrid antibodies
HRP20182174T1 (hr)	2019-02-22	Anti-il-23p19 antitijela proizvedena genetičkim inženjeringom
ZA200905964B (en)	2010-05-26	Engineered anti-il-23R antibodies
GB0708002D0 (en)	2007-06-06	Antibodies
SI2200700T1 (sl)	2016-04-29	Nova protitelesa
GB0821100D0 (en)	2008-12-24	Antibodies
IL198424A0 (en)	2011-08-01	Hybrid immunoglobulins with moving parts
PL2146745T3 (pl)	2015-11-30	Pięcioswoiste przeciwciało
EP2138576A4 (en)	2011-02-23	ANTI-CLAUDIN-4 ANTIBODY
GB0718737D0 (en)	2007-11-07	Antibodies
GB0707505D0 (en)	2007-05-30	Antibodies against il-25
IL207581A0 (en)	2010-12-30	Anti-tyrp1 antibodies
GB0702888D0 (en)	2007-03-28	Novel Antibodies
EP2160407A4 (en)	2011-07-27	NEUTRALIZING ANTIBODIES
IL205073A0 (en)	2010-11-30	Anti-bst2 antibody
GB0817891D0 (en)	2008-11-05	Antibodies against il-25
ZA201007976B (en)	2012-02-29	Anti-pirb antibodies
EP2217626A4 (en)	2011-06-22	EPITOP FOR NEUTRALIZING ANTIBODIES
GB0818356D0 (en)	2008-11-12	Antibodies
HK1126789A (en)	2009-09-11	Engineered anti-il-23r antibodies
HK1144582A (en)	2011-02-25	Engineered anti-tslpr antibodies
GB0724185D0 (en)	2008-01-23	Antibodies
GB0806230D0 (en)	2008-05-14	Antibodies
GB0823562D0 (en)	2009-01-28	Antibodies